We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $596K invested in XTL Biopharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.84% less ownership

Funds ownership: 8.89% → 8.05% (-0.84%)

13% less capital invested

Capital invested by funds: $687K → $596K (-$91K)

33% less funds holding

Funds holding: 6 → 4 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$942

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$35K
2
Citadel Advisors
Citadel Advisors
Florida
-$26K
3
UBS Group
UBS Group
Switzerland
-$2.83K

XTLB Hedge Fund Activity: Q4 2019 in Review

4 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2019, worth a combined $596K — down 13% from $687K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $942. The largest seller was Invesco, exiting entirely with an estimated $35K sold.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2019, down from 6 in Q3 2019.
  • Funds reported $596K of XTL Biopharmaceuticals stock for Q4 2019, down 13% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q4 2019 and 2 closed out, a net change of -2 holders.
  • The largest XTL Biopharmaceuticals buyer in Q4 2019 was Morgan Stanley, an estimated $942 added.
  • The largest XTL Biopharmaceuticals seller in Q4 2019 was Invesco, an estimated $35K sold.

Based on aggregated 13F filings for Q4 2019.